Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Mar;65(3):365–368. doi: 10.1038/bjc.1992.74

Type I interferon resistance in a colorectal cancer cell line is associated with a more aggressive phenotype in vivo.

C A Toth 1, P Thomas 1
PMCID: PMC1977610  PMID: 1558789

Abstract

A type I interferon resistant variant (beta-MIP101) of the poorly differentiated human colon cancer cell MIP101 has a more aggressive phenotype in vivo in the nude mouse. Subcutaneous tumours grew at twice the rate of MIP101, but with similar morphology. beta-MIP101 also produced liver metastases at a higher frequency. beta-MIP101 tumours were diploid while MIP101 tumours were aneuploid. Both cell lines had doubling times of approximately 25 h in vitro.

Full text

PDF
365

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbruzzese J. L., Levin B., Ajani J. A., Faintuch J. S., Saks S., Patt Y. Z., Edwards C., Ende K., Gutterman J. U. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 1989 Jul 15;49(14):4057–4061. [PubMed] [Google Scholar]
  2. Ajani J. A., Rios A. A., Ende K., Abbruzzese J. L., Edwards C., Faintuch J. S., Saks S., Gutterman J. U., Levin B. Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Mod. 1989 Apr;8(2):140–146. [PubMed] [Google Scholar]
  3. Branca A. A. Interferon receptors. In Vitro Cell Dev Biol. 1988 Mar;24(3):155–165. doi: 10.1007/BF02623541. [DOI] [PubMed] [Google Scholar]
  4. Dressler L. G., Seamer L. C., Owens M. A., Clark G. M., McGuire W. L. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer. 1988 Feb 1;61(3):420–427. doi: 10.1002/1097-0142(19880201)61:3<420::aid-cncr2820610303>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  5. Eggermont A. M., Weimar W., Marquet R. L., Laméris J. D., Jeekel J. Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment. Cancer Treat Rep. 1985 Feb;69(2):185–187. [PubMed] [Google Scholar]
  6. GREENWOOD F. C., HUNTER W. M., GLOVER J. S. THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. Biochem J. 1963 Oct;89:114–123. doi: 10.1042/bj0890114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kondo H., Tanaka N., Naomoto Y., Orita K. Antitumor effect of recombinant human interferon-beta and interferon-gamma in combination against human colon cancer cell line in vitro and in nude mice. Jpn J Cancer Res. 1987 Nov;78(11):1258–1265. [PubMed] [Google Scholar]
  8. La Gamma E. F., Goldstein N. K., Snyder J. B., Jr, Weisinger G. Preproenkephalin DNA-binding proteins in the rat: 5' flanking region. Brain Res Mol Brain Res. 1989 Mar;5(2):131–140. doi: 10.1016/0169-328x(89)90004-1. [DOI] [PubMed] [Google Scholar]
  9. Morikawa K., Morikawa R., Killion J. J., Fan D., Fidler I. J. Isolation of human colon carcinoma cells for resistance to a single interferon associated with cross-resistance to multiple recombinant interferons: alpha, beta, and gamma. J Natl Cancer Inst. 1990 Mar 21;82(6):517–522. doi: 10.1093/jnci/82.6.517. [DOI] [PubMed] [Google Scholar]
  10. Niles R. M., Wilhelm S. A., Steele G. D., Jr, Burke B., Christensen T., Dexter D., O'Brien M. J., Thomas P., Zamcheck N. Isolation and characterization of an undifferentiated human colon carcinoma cell line (MIP-101). Cancer Invest. 1987;5(6):545–552. doi: 10.3109/07357908709020314. [DOI] [PubMed] [Google Scholar]
  11. Schiller J. H., Storer B., Bittner G., Horisberger M. A. Characterization of the synergistic antiproliferative effects of interferon-gamma and tumor necrosis factor on human colon carcinoma cell lines. J Interferon Res. 1990 Apr;10(2):129–139. doi: 10.1089/jir.1990.10.129. [DOI] [PubMed] [Google Scholar]
  12. Toth C. A., Thomas P. The effect of interferon treatment on 14 human colorectal cancer cell lines: growth and carcinoembryonic antigen secretion in vitro. J Interferon Res. 1990 Dec;10(6):579–588. doi: 10.1089/jir.1990.10.579. [DOI] [PubMed] [Google Scholar]
  13. Wadler S., Goldman M., Lyver A., Wiernik P. H. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma. Cancer Res. 1990 Apr 1;50(7):2056–2059. [PubMed] [Google Scholar]
  14. Wadler S., Schwartz E. L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res. 1990 Jun 15;50(12):3473–3486. [PubMed] [Google Scholar]
  15. Wadler S., Wersto R., Weinberg V., Thompson D., Schwartz E. L. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res. 1990 Sep 15;50(18):5735–5739. [PubMed] [Google Scholar]
  16. Wagner H. E., Thomas P., Wolf B. C., Zamcheck N., Jessup J. M., Steele G. D., Jr Characterization of the tumorigenic and metastatic potential of a poorly differentiated human colon cancer cell line. Invasion Metastasis. 1990;10(5):253–266. [PubMed] [Google Scholar]
  17. Werner-Wasik M., von Muenchhausen W., Nolan J. P., Cohen S. A. Endogeneous interferon alpha/beta produced by murine Kupffer cells augments liver-associated natural killing activity. Cancer Immunol Immunother. 1989;28(2):107–115. doi: 10.1007/BF00199110. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES